Earnings Releases·Oct 29, 2026, 4:03 PM ET

Gilead Sciences — Third Quarter 2026 Earnings Summary

Total product sales rose 13% year-over-year to $8.3 billion, driven by 18% growth in HIV products and a 42% increase in Trodelvy sales, while Veklury and Cell Therapy revenues declined.
Full-year 2026 product sales guidance was raised to $31.0–$31.3 billion (from $30.1–$30.4 billion), though GAAP and non-GAAP EPS guidance was revised to reflect losses of $(4.40)–$(4.05) and $(1.20)–$(0.85) respectively, primarily due to $9.88 per share in acquired IPR&D charges.
Strategic momentum includes FDA approval for Bixlenvo, European Commission authorization for Trodelvy in first-line metastatic triple-negative breast cancer, and a definitive agreement to acquire PepStar's oral IL-23R inhibitor program.
Capital allocation saw $11.3 billion in acquisitions and $3.1 billion in dividends paid year-to-date, reducing cash and marketable debt securities to $6.4 billion as of September 30, 2026.